Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resminostat - 4SC

Next Previous
Drug Profile

Resminostat - 4SC

Alternative Names: 4SC-201; BYK-408740; Kinselby; RAS-2410; Resminostat-4-SC; YHI-1001

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Hodgkin's disease; Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Cutaneous T-cell lymphoma
  • Phase II Biliary cancer; Hodgkin's disease; Liver cancer; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • No development reported Solid tumours
  • Discontinued Diffuse large B cell lymphoma

Most Recent Events

  • 23 May 2025 4SC receives a negative CHMP opinion for resminostat in Cutaneous T-cell lymphoma in European Union
  • 06 Apr 2025 4SC intends to file response to the EMA’s Day-180 assessment Report within the required deadline
  • 13 Mar 2025 4SC anticipates to receive feedback from the Committee for Medicinal Products for Human Use (CHMP) around the end of April 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top